Core Viewpoint - Pfizer has successfully completed the acquisition of Metsera for approximately $9.2 billion, gaining access to key assets MET-097i and MET-233i, indicating a strategic move in the long-acting weight loss and diabetes treatment market [1] Company Developments - The stock price of Gilead Sciences-B (01672) has increased by 6.25%, reaching HKD 14.46, with a trading volume of HKD 39.59 million [1] - Gilead has developed a subcutaneous reservoir technology platform (ULAP) for long-acting weight loss drugs, positioning itself in the competitive landscape of obesity and diabetes treatments [1] Industry Trends - Eli Lilly and Novo Nordisk are also actively pursuing long-acting platforms, having formed strategic partnerships with Camurus and Ascendis to develop long-acting weight loss and diabetes products by 2025 [1] - Open Source Securities predicts that the value of long-acting pipelines and technology platforms will become more apparent as clinical data is disclosed, suggesting that long-acting therapies will be a key differentiator in the weight loss and diabetes treatment market [1] - Various technologies such as antibody-drug conjugates, fatty acid end-modification, and subcutaneous reservoir sustained-release methods are expected to enable long-acting drug delivery [1]

Summary of Key Points from Conference Call Records Industry Overview - The pharmaceutical industry is generally optimistic, with signs of a rebound in the innovative drug sector. Large-cap companies have seen declines of over 30%, while small-cap companies have dropped more than 50%, indicating a potential opportunity for stock alpha in the coming year [1][2][4]. Key Companies to Watch - **Innovative Drug Sector**: Focus on companies like Innovent Biologics and China National Pharmaceutical Group, as well as smaller firms like Genscript Biotech and Luyin Pharmaceutical [1][4]. - **Medical Devices**: Companies such as Mindray and Spring Medical are highlighted for their recovery and growth potential in high-value consumables and medical equipment [5][6]. - **Traditional Chinese Medicine**: Increased institutional interest, with companies like Yiling Pharmaceutical and China Resources Sanjiu expected to benefit from a recovery in the sector [1][7][9]. - **CRO and API Sectors**: Kanglong Chemical and ProPharma are noted for their growth potential, particularly in clinical research and API business recovery [1][10][11]. Market Trends and Opportunities - **High-Value Consumables**: The pressure from centralized procurement is easing, leading to a reassessment of value driven by innovation [5][6]. - **Blood Products**: The sector is in an adjustment phase but shows signs of reversal, with supply tightening expected in 2026 [3][12][15][16]. - **Oral Peptide Drugs**: New oral formulations like Merck's MK0,616 and Johnson & Johnson's GNG2,113 show promise in treating chronic diseases, with potential to change administration methods and improve patient compliance [3][17][20][27]. Financial Performance and Projections - **Kanglong Chemical**: Expected adjusted net profit of 2.12 billion yuan by 2026, with a price-to-earnings ratio of 25 times [11]. - **ProPharma**: Anticipated to see a compound annual growth rate exceeding 20% by 2027, with a current P/E ratio of about 14 times [11]. - **Tianyu Co.**: Projected profit of 300 million yuan for the year, with a growth rate of over 30% expected [14]. Challenges and Considerations - **Regulatory and Market Dynamics**: The medical device sector faces pressures from policy changes and international competition, necessitating innovation and adaptation [5][6]. - **Blood Product Supply**: The industry is experiencing a supply-demand imbalance, with potential for improvement as new products are introduced [12][15][16]. - **Oral Peptide Development**: Challenges in molecular modification and large-scale production remain significant hurdles for the commercialization of new oral peptide drugs [27]. Conclusion - The pharmaceutical and medical device industries are poised for growth, with several companies showing strong potential for recovery and innovation. Investors are encouraged to focus on key players within these sectors, particularly those involved in innovative drug development and high-value medical devices, as they navigate the evolving market landscape [1][4][5][11][14].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - Major multinational corporations (MNCs) such as Pfizer, Eli Lilly, and Novo Nordisk are actively expanding their long-acting pipelines and technology platforms, with Pfizer's acquisition of Metsera for approximately $9.2 billion being a significant move [4][14] - The report anticipates that long-acting new therapies will become a key competitive direction in the weight loss and diabetes treatment sectors, with increasing clinical data expected to highlight the value of these long-acting pipelines and technology platforms [14][30] Summary by Sections Long-Acting Revolution in Weight Loss - The long-acting revolution in the weight loss sector is being driven by MNCs, with Pfizer's acquisition of Metsera providing access to core assets like MET-097i and MET-233i, which are long-acting GLP-1 receptor agonists and amylin analogs [4][14] - The HALO platform from Metsera allows for significant extension of drug half-lives, with MET-097i and MET-233i having half-lives of approximately 15.8 days and 19 days, respectively [30][31] Key Technologies for Long-Acting Delivery - The report identifies several key technologies for achieving long-acting drug delivery, including: - **Antibody-Drug Conjugation**: A mature technology exemplified by Amgen's AMG133, which is in Phase III clinical trials [18] - **Fatty Acid End Modification**: Gaining attention following Pfizer's acquisition of Metsera, with platforms like MBX's dual fatty acid chain modification technology also in development [24][33] - **Subcutaneous Reservoir Controlled Release**: Widely applicable technology with strategic partnerships formed by Eli Lilly and Novo Nordisk [5][12] - **Peptide Stapling Technology**: Enhances the stability of short peptides, with companies like Zhongsheng Pharmaceutical and Tonghua Dongbao developing relevant products [6][17] Recommended Companies - The report recommends focusing on innovative drugs and their supply chains, particularly in the context of flu-related investment opportunities. Monthly and weekly recommended stocks include: - Monthly: 3SBio, Innovent Biologics, Baillie Gifford, Frontier Biotechnologies, Haofan Biologics, Aopumai, Shanghai Yizhong, WuXi Biologics, Zai Lab, and Fangsheng Pharmaceutical [7] - Weekly: Yuyuan Pharmaceutical, East China Pharmaceutical, Hotgen Biotech, Yaokang Biotech, Bid Pharmaceutical, Haoyuan Pharmaceutical, and Sunshine Novo [7]

Group 1 - The Hong Kong stock market saw a collective decline in the innovative drug sector, with notable drops in several companies [1] - Three-Sixty Pharmaceutical experienced a decline of over 7% [1] - Other companies such as King’s Ray Biotechnology, CSPC Pharmaceutical Group, and Galenica also reported declines [1]

Market Overview - The Hong Kong stock market opened significantly higher on November 20, with the Hang Seng Index at 25,999.78 points, up 169.13 points, a rise of 0.65% [2] - The Hang Seng Tech Index reported 5,646.28 points, increasing by 39.38 points, a gain of 0.70% [4] Company News - China International Capital Corporation (CICC), Xinda Securities, and Dongxing Securities announced a suspension of trading due to a major asset restructuring plan, which involves CICC issuing A-shares to acquire Dongxing and Xinda Securities [6] - Following this news, brokerage stocks collectively surged, with Shenwan Hongyuan Hong Kong (00218.HK) rising over 9%, and other firms like Dongfang Securities (03958.HK) and CITIC Securities (06030.HK) increasing by over 3% [6] Sector Performance - The technology sector saw more gainers than losers, with Baidu up over 3%, Kuaishou and Lenovo rising over 2%, and Alibaba increasing by over 1% [8] - Semiconductor stocks opened higher, with Huahong Semiconductor gaining over 3% [8] - The innovative drug sector mostly rose, with Gilead Sciences up over 3% [8] - Apple-related stocks experienced broad gains, with Hongteng Precision rising over 5% [8] Future Outlook - CITIC Securities' latest report suggests that the Hong Kong market is expected to experience a second round of valuation recovery and performance revival by 2026, driven by a rebound in fundamentals and significant valuation discounts [8] - Investors are advised to focus on five long-term directions: 1) Technology sector, including AI and consumer electronics; 2) Healthcare, particularly biotechnology; 3) Resource commodities benefiting from rising inflation expectations and de-dollarization; 4) Consumer sectors with low valuations expected to recover; 5) Paper and aviation sectors benefiting from RMB appreciation [8]

Investment Rating - The report maintains a "Recommended" rating for the industry [1] Core Views - The report highlights a return of inflation trading, with consumer goods showing a positive trend in performance [1][8] - The overall industry size is significant, with a total market capitalization of 18,186 billion and a circulating market capitalization of 16,721.2 billion [1] Summary by Sections Macroeconomic Analysis - Retail sales growth year-on-year is at 2.9%, with a slight recovery in October due to the holiday effect, showing a month-on-month increase of 0.16% [6] - The restaurant sector saw a year-on-year revenue increase of 3.8% in October, while jewelry sales surged by 37.6% [6][7] - Service retail sales grew by 5.3% year-on-year from January to October, indicating a gradual recovery in service consumption [7] Food and Beverage Sector - October inflation data exceeded expectations, with both CPI and PPI showing improvements, suggesting a potential recovery in profitability for the food and beverage sector [8] - Companies like Haidilao and Anjuke are expected to perform well due to improved demand and operational strategies [9][10] Textile and Apparel Sector - The textile manufacturing sector is experiencing stable overseas demand, with major brands like NIKE showing signs of recovery [12] - Recommendations include focusing on leading manufacturers with optimized order structures and production efficiency [12] Tobacco Sector - The report recommends companies like Smoore International and China Tobacco Hong Kong, highlighting their stable growth and market positioning [16] Home Appliances Sector - The report suggests focusing on leading white goods manufacturers like Midea Group, which has shown stable operational performance [17] Retail and E-commerce - The report notes a significant increase in e-commerce sales during the Double Eleven shopping festival, with a total sales growth of 14.2% [24] - Companies like JD.com are expected to maintain robust growth, with a projected non-GAAP net profit of 318 billion for 2025 [25] Pharmaceutical Sector - The report emphasizes the importance of innovation in the pharmaceutical industry, recommending companies like Innovent Biologics and 3SBio for their strong project pipelines [27] Agriculture Sector - The report indicates a rapid reduction in sow production capacity, suggesting a potential increase in pig prices in 2026 [28]

Market Overview - Global stock markets faced pressure due to a significant drop in US stocks, with the Nasdaq showing a slight recovery by the end of the trading day[2][9] - European markets weakened, with the Stoxx 600 index down 1.01% and the UK FTSE 100 index down 1.11%[9] - The Hang Seng Index fell 1.85%, with major tech stocks experiencing declines[11] Economic Indicators - China's October economic data showed a decline in both supply and demand, with fixed asset investment expected to improve moderately due to new policy tools[4] - The US labor department is set to release the September non-farm payroll report, which could impact market sentiment[4] Commodity and Forex Markets - Geopolitical tensions from Ukraine and Iran led to a 2.39% increase in international oil prices, with NY crude oil reaching $60.09 per barrel[26] - Gold prices fell over 2% as expectations for a Federal Reserve rate cut diminished, with NY gold priced at $4,094.2 per ounce[26] Fixed Income Market - UK bond yields rose significantly, with increases of 7-16 basis points, reflecting concerns over fiscal health[30] - US Treasury yields also increased, with the 10-year yield rising to 4.15%[30] Company Performance - Dingdong Maicai reported a slight revenue increase of 1.9% year-on-year, but faced a 37.3% decline in non-GAAP net profit due to competitive pressures[7] - Monday.com achieved a 26% year-on-year revenue growth but provided a lower-than-expected Q4 guidance, causing stock price concerns[7]

Market Performance - The Hang Seng Index and the National Enterprises Index closed at 26,572 points and 9,398 points, respectively, with weekly increases of 1.3% and 1.4%[1] - Total trading volume in Hong Kong stocks was HKD 116.49 billion, similar to the previous week's HKD 115.18 billion, indicating a cautious market sentiment[1] Sector Performance - Healthcare, real estate, consumer staples, materials, and energy sectors rose by 7.2%, 5.0%, 3.8%, 3.0%, and 2.5% respectively, while consumer discretionary, industrials, and utilities fell by 0.8%, 0.7%, and 0.1%[1] - JD Health (6618 HK) and China Resources Mixc Lifestyle (1209 HK) led the blue-chip stocks with increases of 15.6% and 12.8%, while Xinyi Solar (968 HK) and Baidu Group (9888 HK) saw declines of 6.3% and 5.9%[1] Economic Indicators - China's fixed asset investment in October decreased by 1.6%, a larger drop than September's 0.1%[3] - The industrial value-added growth for October was 4.9%, down from 6.5% in September[3] - Hong Kong's GDP grew by 3.8% year-on-year in Q3, up from 3.1% in Q2, prompting the government to raise its full-year growth forecast from 2-3% to 3.2%[3] Consumer Trends - Retail sales in October reached CNY 4.6291 trillion, with a year-on-year increase of 2.9%[4] - The new round of national subsidies and the early start of the Double 11 shopping festival contributed to the upward trend in retail sales[4] - The consumer sector in Hong Kong saw a significant rebound, with an average increase of 7.7% in new consumption stocks last week[4] Industry Developments - The healthcare index rose by 6.8%, outperforming the Hang Seng Index, with notable gains in innovative drug stocks[4] - The energy sector faced declines, particularly in the solar panel segment, with Xinyi Solar and other companies experiencing significant drops due to falling silicon prices[5] - Recent policy revisions by the National Development and Reform Commission aim to support the natural gas supply chain, benefiting downstream operators[5]

Core Viewpoint - The financial markets are experiencing volatility due to mixed signals from the Federal Reserve regarding interest rate policies, geopolitical tensions, and sector-specific performance in both U.S. and international markets [3][4][11]. Market Performance - U.S. stock indices showed mixed results with the Dow Jones down 0.65%, S&P 500 down 0.05%, and Nasdaq up 0.13% [4][8]. - European indices faced declines, with Germany's DAX30 down 0.69%, UK's FTSE 100 down 1.11%, and the Euro Stoxx 50 down 0.85% [4][8]. - Hong Kong's Hang Seng Index fell 1.85%, closing at 26,572.46 points, with significant declines in technology stocks [5][8]. - A-shares also declined, with the Shanghai Composite Index down 0.97%, closing below 4,000 points [6][9]. Commodity Prices - WTI crude oil prices rose by 2.13%, closing at $59.82 per barrel, while Brent crude increased by 0.22% to $63.95 per barrel [4][8]. - Gold prices fell by 2.2%, ending at $4,079.58 per ounce, and silver dropped by 3.4% to $50.56 per ounce [8][9]. Federal Reserve Signals - Federal Reserve officials, including Logan and Schmidt, issued strong hawkish signals, indicating that further rate cuts may not be appropriate at this time [11]. - The market is reacting to these signals, with expectations of interest rate stability impacting various asset classes [11]. Corporate Developments - Berkshire Hathaway disclosed a rare technology stock position, having built a stake in Alphabet, Google's parent company, during Q3 [11]. - Huawei is expected to announce breakthrough technologies in the AI sector, which could enhance computational resource efficiency [17].

Investment Rating - The report maintains an investment rating of "Outperform" [4] Core Insights - The innovative drug sector is experiencing a surge in business development (BD) transactions, with expectations for multiple BD deals to emerge in Q4 2025. As of October 2025, there have been 175 overseas licensing BD transactions in the domestic innovative drug sector, with a total contract value of $104.2 billion and upfront payments reaching $8.1 billion, surpassing the total figures for the entire year of 2024 [2][17][18]. Summary by Sections Weekly New Drug Market Review - From November 10 to November 16, 2025, the top five gainers in the new drug sector were: - Gilead Sciences (+45.40%) - Lai Kai Pharmaceutical (+27.93%) - Jiahe Biopharma (+24.61%) - Zhongsheng Pharmaceutical (+24.46%) - Kaitu Pharmaceutical (+22.81%) - The top five losers were: - Yongtai Biopharma (-7.74%) - Junsheng Tai (-7.43%) - Weixin Biopharma (-1.87%) - Zai Ding Pharmaceutical (-0.93%) - Maibo Pharmaceutical (-0.00%) [1][13][15] Recommended Focus Stocks - The report suggests focusing on several stocks with potential catalysts, including: 1. Products with high overseas sales certainty certified by MNCs: - PD-1 upgraded product: Sanofi - GLP-1 asset: Lianbang Pharmaceutical - ADC asset: Kelun-Botai 2. Potential heavyweights for overseas licensing from MNCs: - PD-1 upgraded product: Kangfang Biopharma - Breakthroughs in autoimmune fields: Yifang Biopharma, China Antibody - Innovative target ADC: Fuhong Hanlin, Shiyao Group 3. Stocks likely to benefit from medical insurance negotiations and commercial insurance innovative drug directories: - Expected beneficiaries from medical insurance directory: Hengrui Medicine, Kangnuo Pharmaceutical, Maiwei Biopharma, Zhixiang Jintai, Haichuang Pharmaceutical - Expected beneficiaries from commercial insurance innovative drug directory: WuXi AppTec, Kexin Pharmaceutical [2][17] New Drug Approval and Acceptance - This week, four new drugs or new indications received approval, and six new drugs or new indications were accepted for review [3][24]. Clinical Application Approval and Acceptance - This week, 43 new drug clinical applications were approved, and 43 new drug clinical applications were accepted [7][27].